Table 2.
Details of the antibodies used in this study
| Antibody | Manufacturer | Clone | Dilution for frozen section | Dilution for FFPE section |
|---|---|---|---|---|
| Spectrin | Novocastra | RBC2/3D5 | 1:200 | 1:20 |
| Dystrophin (rod domain) | Novocastra | Dy4/6D3 | 1:100 | 1:20 |
| Dystrophin (C-terminus) | Novocastra | Dy8/6C5 | 1:100 | 1:50 |
| Dystrophin (N-terminus) | Novocastra | Dy10/12B2 | 1:50 | 1:20 |
| α-sarcoglycan | Novocastra | AD1/20A6 | 1:200 | 1:50 |
| β-sarcoglycan | Novocastra | bSarc1/5B1 | 1:200 | 1:50 |
| γ-sarcoglycan | Novocastra | 35DAG/21B5 | 1:50 | 1:20 |
| β-dystroglycan | Novocastra | 43DAG/8D5 | 1:300 | 1:20 |
| Dysferlin | Novocastra | Ham1/7B6 | 1:50 | 1:20 |